However, blood lipid management is not as simple as taking medications with a sip of water. Over the past century, experts in the blood lipid field have been continuously debating, collaborating, and investigating effective ways to better optimize blood lipid management. However, many questions that have puzzled clinicians remain, including the necessity of establishing a target value in lipid-lowering therapy, the level to which low-density lipoprotein cholesterol (LDL-C) should be reduced, acceptance of the "cholesterol hypothesis" or the "statin hypothesis," whether statins are pleiotropic, and whether statin therapy or lipid-lowering therapy should be intensified. Recently, the results of many large clinical studies and the publication of authoritative guidelines have inspired as well as directed the advancement of blood lipid management in China.
is it necessary to establish a target Value in lipid-lowering therapy?
The 2013 American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults [1] (hereinafter referred to as the "ACC/AHA Guideline") shattered previous beliefs and replaced the cholesterol-lowering target value with the intensity of statin therapy, based on the lack of support for specific lipid targets from evidence-based medicine. This ACC/AHA Guideline position was immediately disputed by various parties. Subsequently, guidelines in both the "National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia" [2] issued by the US National Lipid Association (NLA) and the "Global Recommendations for the Management of Dyslipidemia" [3] issued by the International Atherosclerosis Society retained the cholesterol-lowering target value, which initiated the dispute.
With the development of evidence-based medicine, knowledge regarding nonstatin lipid-lowering drugs and lipid-lowering treatment goals is expanding and has gradually become validated. After reexamining such evidence, the ACC issued the "Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease (ASCVD) Risk" [4] in 2016, in which the most important change was that statins were no longer considered the only important treatment, which reinstituted the LDL-C target to compensate for the shortcoming and bias of the 2013 ACC/AHA Guideline.
That same year, the "European Society of Cardiology (ESC)/ European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias" [5] (hereinafter referred to as the "ESC Lipids Guide") and the "China Adult Blood Lipids Prevention Guide" [6] (hereinafter referred to as the "China Lipids Guide") were published and firmly recommended the LDL-C management target, ending the debate. The 2016 China Lipids Guide clearly indicated that abolishing the lipid-lowering target would seriously affect the compliance of patients taking lipid-lowering drugs and that long-term lipid-lowering therapy is a key benefit, which is particularly important for Chinese patients whose treatment compliance is generally poor. The guidelines set a clear LDL-C target based on different risk levels of ASCVD for clinicians to follow and use as a reference value.
to what leVel should the low-density lipoprotein cholesterol be reduced in blood lipid ManageMent?
The benefit of LDL-C reduction in lipid management is affirmed; however, because an LDL-C lowering goal is also needed, the question remains to what level the LDL-C should be reduced. In the previous guidelines, different LDL-C goals were set according to the different levels of patient cardiovascular risk, and the higher the risk level, the more stringent the LDL-C goal. In addition, the LDL-C target for patients at very high risk has tended to decrease recently. The 1991 US National Cholesterol Education Program Adult Treatment Panel II (NCEP ATP II) Guideline recommended that LDL-C be reduced to <2.6 mmol/L (100 mg/dl), and the updated 2004 ATP III Guideline recommends that LDL-C be reduced to <1.8 mmol/L (70 mg/dl). [7] Currently, major guidelines, including the 2016 ESC Lipids Guide and the China Lipids Guide, all established LDL-C <1.8 mmol/L (70 mg/dl) as the target for very high-risk populations, in whom the ESC Lipids Guide for the first time proposed an LDL-C lowering by at least 50% in very high-risk patients with a baseline level of 70~135 mg/dl, [5] while the China Lipids Guide for the first time recommended that LDL-C levels be further lowered by approximately 30% in very high-risk patients with an LDL-C within the target range. [6] Recently, the American Association of Endocrinologists (AACE) and the American Society of Endocrinology (ACE) jointly issued the "American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease" (hereinafter referred to as the "AACE/ACE Guide") which newly added the ultra-high-risk level and set its corresponding LDL-C target to 55 mg/dl, [8] based on the finding of The IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) study [9] that an LDL-Clevel reduction to 53.2 mg/dL was still beneficial.
Clearly, whether maintaining LDL-C at a very low level for a long period would be harmful to humans remains unknown, which will only be clarified following many long-term studies.
the adherence status Quo of china Very high-risk patients
With the increasing emphasis on blood lipid management and more drug options, whether the blood lipid therapeutic adherence of China's very high-risk patients has improved remains in question. In the second survey on the clinical status of lipid control in China conducted in 2006, the LDL-C compliance rate of the very high-risk patients was 38%. [10] Moreover, in the DYSlipidemia International Study (DYSIS-China study) [11] conducted in 2012, after lipid-lowering therapy was administered for at least 3 months, the LDL-C compliance rate of the very high-risk patients remained lower than 30%. The higher the patient risk level, the more the patient benefited from intensive lipid-lowering management. However, real-world situations are divergent and the compliance status quo of China's very high-risk patients is not a basis for optimism. The reason for this conclusion is, in addition to the rising trend of LDL-C levels among China's untreated patients with coronary heart disease, [12] the intolerance of and poor compliance with statin therapy. [13] Statins are the most commonly used cholesterol-lowering drugs in clinical practice. To meet the need for intensive lipid-lowering therapy in extremely high-risk patients, in the past, clinicians prescribed a high dose of a statin as the only option. However, the statin therapy "rule of six" maintains that even when the statin dose is doubled, which is accompanied by a proportional increase in the cost of the drugs, the incremental LDL-C lowering effect is quite small. Moreover, statin treatment is associated with dose-dependent statin-related adverse effects. Moreover, high-dose statin monotherapy significantly increases the incidence of adverse events such as those affecting muscle and liver, for example, [14] leading to drug cessation and switching, thereby affecting the statin therapy compliance rate. Multiple reliable international guidelines have indicated that Asians should not use high-strength/high-dose statins, [1, 2, 4, 5] citing high-intensity statin treatment is associated with an increased risk of elevated liver enzyme levels, which is particularly prominent in the Chinese population. High-intensity statin therapy is clearly not the choice for intensive lipid-lowering treatment of the Chinese population, and the preferred intensive lipid-lowering treatment for very high-risk patients remains undetermined.
cholesterol hypothesis or statin hypothesis?
Before an ideal intensive lipid-lowering strategy for very high-risk patients is selected, it must first be determined whether the benefit of cholesterol-lowering therapy is derived from the "cholesterol hypothesis" or the "statin hypothesis," which has been one of the controversial topics in the blood lipid field for nearly half a century.
The "statin hypothesis," once very popular, maintains that the effect of statins on reducing cardiovascular risk should not be interpreted entirely by the lowered LDL-C level. Statins have many biological effects other than lowering cholesterol, such as improving endothelial dysfunction, reducing platelet aggregation, increasing nitric oxide bioavailability, myocardial protection, antioxidant effects, inflammation inhibition, and other anti-atherosclerotic effects, that is, the so-called "biological pleiotropism" [15] of statins. Therefore, the unique therapeutic effect of statins on atherosclerotic disease is achieved not merely by reducing the LDL-C level but also by other additional actions, that is, "the higher the statin dose, the greater the clinical benefit." Therefore, the efficacy of statins cannot be extended to other cholesterol-lowering drugs. This hypothesis has been supported by some clinical trials with a small sample size, in which the inclusion of nonstatin cholesterol-lowering drugs lowered the LDL-C level but did not reduce the incidence and mortality of cardiovascular events compared with the patients in whom only statins were used. In this context, the 2013 ACC/AHA Guideline removed the recommendation of non-statin cholesterol-lowering drugs and instead emphasized the recommendation of statin therapy only, including high-intensity statins for ASCVD or patients at risk for cardiovascular disease. [1] The IMPROVE-IT study [9] published in 2015 is a landmark study in the field of blood lipids, the results of which are consistent with those of the meta-analysis by the Cholesterol Treatment Trialists" Collaboration, and suggested that the LDL-C-lowering efficacy of ezetimibe, a nonstatin drug, did not differ from that of statins, which thus questioned the so-called "pleiotropism" of statins. In a comment published in the New England Journal of Medicine (NEJM), Dr. John et al. [16] argued that after the IMPROVE-IT study, the "cholesterol hypothesis" should be renamed the "LDL Principle," that is, regardless of the type and dose of lipid-lowering drugs, including combination therapy with other drugs, LDL-C reduction is the key. Indeed, the role of an ezetimibe-containing combination therapeutic strategy has gained increasing prominence in intensive lipid-lowering therapies. The results of the follow-up Plaque REgression with Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS) study [17] also showed that when compared with statin monotherapy, the LDL-C decrement achieved by the ezetimibe combination therapy exhibited the same plaque reversal effect. The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) study [18] of proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reported by the ACC this year reconfirmed the "LDL Principle," which signaled the demise of the "statin hypothesis." The pleiotropic effect of statins was also unsubstantiated in several large-scale investigations, including the China Intensive Lipid Lowering With Statins in Acute Coronary Syndrome trial, [19] Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention study, [20] the Asian Lipitor Pretreatment in ACS study, [21] and the Statin Therapy in Cardiac Surgery study. [22] The 2016 China dyslipidemia guide 6 also clearly stated that "the size of clinical benefit of statins in reducing ASCVD events is positively correlated with the decrement of LDL-C and that the clinical benefit of statin therapy is derived from the LDL-C reducing effect." In April 2017, the EAS published the "LDLs cause atherosclerotic cardiovascular disease: A consensus statement from the European Atherosclerosis Society Consensus Panel" [23] conclusive review. Through a comprehensive analysis of more than 200 prospective epidemiological, genetic, and Mendelian randomized studies as well as randomized clinical trials, the consensus confirmed the existence of a strong logarithm linear correlation between the absolute LDL-C level and ASCVD risk, that reducing LDL-C levels reduces ASCVD risk, and that this benefit is proportional to the LDL-C decrement, regardless of the drug used.
for Very high-risk patients, should intensiVe statin therapy or intensiVe lipid-lowering therapy be used?
The return of the "LDL principle" has broken the monopoly of statins. With the development of the nonstatin drug ezetimibe and PCSK9 inhibitor-related investigations, the status of combination lipid-lowering therapy in blood lipid management has been greatly enhanced. The 2016 China dyslipidemia guide indicated that the combination of lipid-lowering drugs is likely the trend of dyslipidemia intervention, with the advantage of improving the compliance rate of lipid control while reducing the incidence of adverse reactions. [6] Ezetimibe is currently the world's only commercialized cholesterol absorption inhibitor and when combined with statins may complement statins to further enhance the cholesterol-lowering effect. [24] The LDL-C decrement achieved by the combination of 10 mg/d of ezetimibe and 10 mg/d of atorvastatin was reportedly [25] equivalent to that achieved by 80 mg/d of atorvastatin, that is, 1 + 1 = 8. In terms of safety, the combination therapy did not increase the risk of adverse events and was shown to be equivalent to that of the statin monotherapy, [26] that is, 1 + 1 = 1. Moreover, in terms of the performance-to-price ratio, the daily cost of the combination therapy (10 mg/day of ezetimibe and 10 mg/day of atorvastatin) was less than half the cost of the statin monotherapy (80 mg/ day of atorvastatin). Even without considering the limitations of high-dose statin clinical treatment (the statin "rule of 6," dose-dependent adverse reactions), the combination therapy of ezetimibe with a moderate statin dose undoubtedly provides a new clinical intensive lipid-lowering option. For very high-risk patients, the combination therapy is clearly effective, well tolerated, and more cost-effective, which are conducive to improving patients' long-term medication compliance.
After the publication of the IMPROVE-IT study, a number of respected international guidelines have been updated accordingly and actively recommend ezetimibe combination therapy. [2, [4] [5] [6] The 2016 ACC/AHA nonstatin lipid-lowering therapy expert consensus [4] not only established ezetimibe as the first choice of nonstatin lipid-lowering drug therapy for the populations that clearly benefit from the four categories of cholesterol-lowering therapy but also extended ezetimibe use to the coronary heart disease population from the acute coronary syndrome population that had demonstrated benefits published in the IMPROVE-IT study. The 2016 China dyslipidemia guide is clearly against the use of high-intensity statins in the Chinese population, and the combination therapy of ezetimibe with a moderate-intensity statin is the only intensive lipid-lowering regimen recommended by the guideline (Category I recommendation, Level B evidence).
[6]
Summary
The centuries-old history of cholesterol illustrates a process of continuous reflection and continuous progress, driven by substantial clinical research evidence. In view of the changes in the European and American guidelines, the international community has notably switched from the 2013 ACC/AHA Guideline, [1] in which high-intensity statin therapy was the only option, to the recommendations of the 2016 ACC Non-Statin Consensus [4] and 2016 ESC Lipids Guide, [5] in which the maximum tolerated statin dose is proposed. This direction is a clear indication that the Asian population, older adults, and female patients are not suitable for the use of high-intensity statins. This rational return reflects not only the scientific spirit of self-correction and self-improvement but also a temporal shift during which the "cholesterol theory" evolved from ambiguity to its validated return, and the evolution of blood lipid treatment strategy from a sole option to combination therapy with various lipid-lowering drugs. In fact, drug combination therapy was never an unfamiliar regimen; currently, it is inconceivable to not use drug combination therapy in the fields of blood pressure and blood sugar treatment. Therefore, we should choose an ideal treatment regimen that comprehensively considers efficacy, safety, and compliance to implement a more aggressive lipid-lowering treatment strategy.
Many unanswered questions remain in the lipids field and the newly developed drugs and newly proposed views require further verification. For example, the question of whether the cholesterol esterase transfer protein (CETP) inhibitors will eventually be adopted is unclear. The efficacy and safety of other lipid-lowering drugs (e.g., apolipoprotein B 100 synthesis inhibitors, microsomal triglyceride transfer protein inhibitors, etc.) need to be addressed. Whether apolipoprotein A1, apolipoprotein B, and CETP are new therapeutic targets or pathways is also unclear. On June 27, 2017, Merck announced that the REVEAL (the Randomized Evaluation of the Effects of Anacetrapib Through Lipid-modification) outcomes study of anacetrapib met its primary end-point, significantly reducing major coronary events compared to placebo in patients at risk for cardiac events already receiving an effective LDL-C lowering regimen. The results of REVEAL study will be presented at the ESC meeting on August 29, 2017.
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